REGEN BIOPHARMA, INC. (RGBP) Net income 2017–2026
REGEN BIOPHARMA, INC. (RGBP) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$1.3MFY2026 · since FY2017: -$7.8M → -$1.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$1.3M | -90.7% |
| FY2025 | -$668,255 | -157.8% |
| FY2024 | $1.2M | -52.7% |
| FY2023 | $2.4M | +136.1% |
| FY2022 | -$6.8M | -298.1% |
| FY2021 | $3.4M | +230.2% |
| FY2020 | -$2.6M | +44.4% |
| FY2019 | -$4.7M | +19.2% |
| FY2018 | -$5.8M | +24.7% |
| FY2017 | -$7.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBP financial trends
RGBP RevenueRGBP Net marginRGBP Gross profitRGBP Gross marginRGBP Operating incomeRGBP Operating marginRGBP Operating cash flowRGBP Free cash flowRGBP Capital expendituresRGBP Return on equityRGBP Stock buybacksRGBP Dividends paidRGBP Total assetsRGBP Total liabilitiesRGBP Shareholders’ equityRGBP overview →